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Calcitriol is a standard therapy for secondary
hyperparathyroidism in chronic renal failure. We evaluated
whether the effect of daily or intermittent calcitriol
administration is more efficient in enhancing bone growth in
renal failure with advanced secondary hyperparathyroidism
in weanling 5/6 nephrectomized rats loaded with
phosphorus to induce severe secondary
hyperparathyroidism. The animals were treated daily or three
times weekly with calcitriol for 4 weeks but the total weekly
dose of calcitriol was the same. Although calcitriol increased
the serum calcium, it did not lower parathyroid hormone
(PTH) or improve tibia and body length. Animals with renal
failure and advanced secondary hyperparathyroidism had
decreased PTH/PTHrP, which was accompanied by an
increase in the cyclin kinase inhibitor p57Kip2. Calcitriol
treatment upregulated the PTH/PTHrP receptor but also
increased inhibitors of cell proliferation such as p21Waf1/Cip1,
IGFBP3, and FGFR3. Calcitriol also enhanced markers of
chondrocyte differentiation, such as IGF1, Vitamin D receptor,
FGF23, and bone morphogenetic protein-7. Receptor
activator of nuclear factor-jb ligand levels improved with
calcitriol treatment but without changes in osteoprotegerin
suggesting an enhancement of osteo/chondroclastogenesis
and mineralization. Overall, both daily and intermittent
calcitriol had similar effects on endochondral bone growth in
phosphorus-loaded rats with renal failure.
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Calcitriol is a standard treatment for secondary hyperpara-
thyroidism and renal bone disease. Whether daily calcitriol
administration is more effective than intermittent therapy in
improving growth in children with chronic renal failure and
advanced secondary hyperparathyroidism remains to be
defined. In pediatric patients with Stage 3–4 chronic renal
failure with mild elevations of parathyroid hormone (PTH),
daily calcitriol was equally effective as intermittent therapy in
the reduction of PTH and enhancement of growth.1,2 A
greater improvement of osteitis fibrosa was demonstrated
during intermittent calcitriol therapy in children maintained
on peritoneal dialysis with refractory secondary hyperpar-
athyroidism, although 30% of the patients developed low
turnover bone.3 Conversely, Mehls et al. reported that only
daily calcitriol and not intermittent administration enhanced
growth in rats with renal failure after 2 weeks of treatment.4
The divergence of growth findings in these studies suggests
that daily and intermittent calcitriol may have different
effects on endochondral bone growth. In the growth plate,
calcitriol has dose-dependent inhibitory effects on chondro-
cyte proliferation and matrix synthesis.5,6 The aim of the
current study is to assess the effects of daily or intermittent
calcitriol on chondrocyte proliferation and differentiation in
young rats with renal failure and advanced secondary
hyperparathyroidism.
RESULTS
Anthromorphic measurements
Weight gain did not differ in nephrectomized and control
animals (Table 1). At the end of the study, body length was
16–19% less in Nx-Phos and in both calcitriol groups
compared with Control (Table 1). Tibial length was 6–9%
shorter in calcitriol and Nx-Phos groups (Table 1). Food
efficiency ratio was used to evaluate growth under conditions
of controlled food intake;7 the values did not differ in all
groups (Table 1).
Serum biochemical parameters
Bioactive PTH levels increased more than 40-fold in all
nephrectomized animals and did not change after 4 weeks of
daily or intermittent calcitriol (Table 2). Serum phosphorus,
creatinine, and urea nitrogen were much higher in nephrec-
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tomized groups (Table 2). Calcitriol increased serum calcium
in Nx-Phos animals comparable with Control (Table 2). There
was a positive correlation between calcium and tibial length,
R¼ 0.4, Po0.03, but serum phosphorus and PTH negatively
correlated with body and tibial length, R¼0.7, Po0.007.
Growth plate morphometry
The width of the growth plate was 20–30% shorter in
phosphorus-loaded rats (Figure 1). There was no difference
in the ratio between the proliferative zone and the growth
plate, 0.570.005, P¼NS, and between the hypertrophic zone
and the total width in all groups, 0.470.05, P¼NS
(Figure 1). The columnar architecture of the growth plate
was nearly restored after 4 weeks of treatment with either
daily or intermittent calcitriol (Figure 1).
To evaluate whether daily or intermittent calcitriol has
divergent effects on chondrocyte proliferation, several
markers of cell proliferation were evaluated: PTH/PTHrP
receptor, cyclin D1, histone-4, mTOR (mammalian target of
rapamycin), Col2a1, and b1 integrin. In the growth plate, b1
integrin is critical in the maintenance of the columnar
architecture, cell-to-extracellular matrix attachment and may
Table 1 | Anthropometric measurements and food efficiency ratio in all groups
Nx-Phos N=8 Nx-Daily D N=9 Nx-Int D N=9 Control N=10
Change in body weighta (g) 138734 139720 140733 151720
Change in body lengtha (cm) 12.171.1b 11.871.1b 12.171.0b 1471.1
Tibial lengthc (cm) 3.570.1d 3.670.1d 3.670.1d 3.870.09
Food efficiency ratioe 3.371.2 3.371.0 3.370.8 3.070.3
aDifference between final and baseline measurements.
bPo0.05 versus Control.
cObtained at the time of killing.
dPo0.01 versus Control.
eTotal food consumed/weight gain during the study period.
Table 2 | Serum biochemical measurements in all groups
Nx-Phos N=8 Nx-Daily N=9 Nx-Int D N=9 Control N=10
Bioactive 1-84PTH (ng/l) 11927403a 13627685a 13477286a 29710
Calcium (mmol/l) 2.070.3b 2.470.1 2.370.1 2.570.06
Phosphorus (mmol/l) 4.471.0a 4.071.1a 4.170.9a 3.170.3
Urea nitrogen (mmol/l) 2375a 29712a 27710a 872
Creatinine (mmol/l) 88735a 97732a 88734a 2779
aPo0.0001 versus Control.
bPo0.0002 versus all groups.
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Figure 1 | Measurements of the width of the growth plate, proliferative zone, and hypertrophic zone in all groups (upper panel) and
the corresponding photomicrographs in the lower panel,  65. Note the disorganized growth plate architecture in the Nx-Phos group.
Kidney International (2007) 72, 582–591 583
CP Sanchez and YZ He: Calcitriol and bone elongation o r i g i n a l a r t i c l e
affect chondrocyte proliferation.8 In the current study, b1
integrin localized to the upper hypertrophic chondrocytes
and declined in Nx-Phos but increased twofold with calcitriol
(Figure 2a). Likewise, Col2a1 (type II collagen, Figure 2b) in
the extracellular matrix and the proteoglycan aggrecan
(Figure 2c) improved with calcitriol.
In agreement with our previous studies, PTH/PTHrP
receptor, an essential regulator of chondrocyte proliferation,
declined in phosphorus loaded animals and improved with
calcitriol;9 3673% in Nx-Phos, 7479% in Nx-Daily D,
7271% in Nx-Int D, and 8072% in Control, Po0.02.
Cyclin D1 is essential in the progression through the G1 phase
of the cell cycle and highly responsive to stimulation by
growth factors, including PTH/PTHrP. Our findings showed
that cyclin D1 localized to the proliferating chondrocytes and
it was twofold lower in the Nx-Phos group. With an increase
in PTH/PTHrP receptor, there was a concomitant enhance-
ment of cyclin D1 in both calcitriol groups (Figure 3a).
Histone-4, which also localized to the proliferative zone,
declined by 80% in the Nx-Phos and increased three- to
fourfold with calcitriol but remained lower than Control
(Figure 3b). The mTOR is an important factor in cell cycle
progression, which can enhance the translation of cyclin D1.
The protein expression of mTOR was restricted to the
proliferating chondrocytes and the protein expression
declined by 35% in Nx-Phos and increased by 20% with
calcitriol (Figure 3c). Our current findings suggest that
calcitriol may directly increase PTH/PTHrP receptor with
subsequent enhancement of other cell cycle proteins
although, the expression remained lower in all nephrecto-
mized groups compared with animals with normal renal
function. The decline in PTH/PTHrP receptor was accom-
panied by an upregulation of the cyclin-dependent kinase
inhibitor p57Kip2 by 40% in the hypertrophic chondrocytes of
nephrectomized animals independent of calcitriol; this
change may promote chondrocyte hypertrophy and hinder
cell proliferation (Figure 4a).
Calcitriol has been demonstrated to enhance mineraliza-
tion and increase chondrocyte differentiation. To assess the
effects of daily and intermittent calcitriol on chondrocyte
maturation, the following proteins associated with cell
differentiation were used, including CaR, IGF-I, IGFBP-3,
p57Kip2, p21Waf1/Cip1, FGF23, FGFR3, VDR, and BMP-7
expression. As previously discussed, daily or intermittent
calcitriol did not affect p57Kip2 but increased another cyclin-
dependent kinase inhibitor p21Cip/Waf, which also localized to
the hypertrophic chondrocytes (Figure 4b). Likewise, bone
morphogenetic protein-7 (BMP-7) that has been associated
with chondrocyte maturation was localized to the hyper-
trophic chondrocytes and the expression of BMP-7 was
downregulated in phosphorus-loaded rats and increased in
both calcitriol groups (Figure 4c).
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Figure 2 | Upregulation of b1 integrin, Col2a1, and aggrecan expression during calcitriol therapy in chondrocytes. The protein expression
of b1 integrin (a) located in the hypertrophic chondrocytes as denoted by arrows (brown color, left panel,  65) and the corresponding
quantification (right panel). Col2a1 (type II collagen) protein expression (b) in the extracellular matrix of the growth plate (brown color,  25) in
all groups; lighter staining was evident in Nx-Phos group. Aggrecan protein expression (c) localized intracellularly and along the cell
membrane of the hypertrophic chondrocytes (denoted by arrows, left panel,  65) and the corresponding Labeling index (right panel).
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Figure 3 | Markers of chondrocyte proliferation, cyclin D1, histone-4, and mTOR, increased during treatment with calcitriol. (a) Cyclin D1,
(b) histone-4, and (c) mTOR protein expression localized to the proliferating chondrocytes, denoted by arrows (left panel,  65) and
corresponding Labeling index in the right panel.
0
20
40
60
80
100
120
140
La
be
lin
g 
in
de
x
a
aP<0.0001 versus control
Nx-Phos Nx-Daily D Nx-Int D Control
Nx-Phos Nx-Daily D Nx-Int D Control
Nx-Phos Nx-Daily D Nx-Int D Control
a
a
Nx-Phos Nx-Daily D Nx-Int D Control
Nx-Phos Nx-Daily D Nx-Int D Control
0
20
40
60
80
100
La
be
lin
g 
in
de
x
a
aP<0.05 versus Nx-Phos, control
a
0
20
40
60
80
100
120
La
be
lin
g 
in
de
x
a
aP<0.002 versus all groups
bP<0.05 versus control
b
b
Nx-Daily D Nx-Int D Control
4
Nx-Phos
a
b
c
Figure 4 | Enhancement of p57Kip2 in renal failure and increase in p21Cip/Wafand BMP-7 during calcitriol therapy. (a) Cyclin-dependent kinase
inhibitor p57Kip2 localized in the hypertrophic chondrocytes, (b) p21Cip/Waf in the terminal chondrocytes, and (c) BMP-7 localized in the hypertrophic
chondrocytes, denoted by arrows and brown color (left panel,  65). Labeling index is illustrated in the corresponding panels on the right.
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CaR is a G-protein-coupled receptor essential in both
chondrocyte proliferation and chondrocyte maturation.10 Our
results showed that CaR, which localized to the lower
proliferating and upper hypertrophic chondrocytes, declined
by 40% in Nx-Phos and was restored with calcitriol (Figure 5a).
In contrast to our previous studies in rats with renal failure
and mild secondary hyperparathyroidism, IGF-I expression
increased with both daily and intermittent calcitriol but
remained 15–20% lower than Control (Figure 5b). Calcitriol
has been reported to promote cell differentiation and inhibit
proliferation by upregulating IGFBP-3; this maybe related to the
enhancement of the differentiation process through an IGF-I-
dependent or -independent pathway.5 IGFBP-3, a well docu-
mented inhibitor of cell proliferation,11 declined in phosphorus-
loaded animals and increased with daily and intermittent
calcitriol by approximately 35% (Figure 5c).
Vitamin D receptor (VDR) expression was most intense in the
hypertrophic chondrocytes. Calcitriol whether given daily or inter-
mittently significantly upregulated its own receptor (Figure 6a).
FGF23 is an important regulator of serum phosphorus. It is
well documented that phosphorus is important in chondro-
cyte differentiation and mineralization.12,13 Currently, there
are no published studies to demonstrate the localization and
role of FGF23 in the growth plate cartilage in renal failure. Our
results show that FGF23 protein localized to the hypertrophic
chondrocytes and may play a role in chondrocyte maturation
(Figure 6b). FGF23 was 35% lower in Nx-Phos compared with
Control and substantially increased by 1.5 times with calcitriol
without any changes in serum phosphorus (Figure 6b). FGF23
expression did not correlate with serum phosphorus or PTH.
FGFR3, a negative regulator of chondrogenesis, declined in
Nx-Phos and increased with calcitriol (Figure 6c). Upregula-
tion of FGFR3 as demonstrated in achondroplasia may induce
premature exit of proliferating chondrocytes into hypertrophy
leading to shorter bone growth.14
Osteo/chondroclastic resorption is a necessary step
towards mineralization and bone formation. The regulation
of osteoclast formation and function are tightly regulated by
the receptor activator of nuclear factor-kb ligand (RANKL),
which induces osteoclastogenesis and its decoy receptor
osteoprotegerin (OPG). Osteoclastogenesis can also be
determined by the relative ratio between RANKL and OPG;
an increase in RANKL enhances bone resorption, increases
proteolytic enzymes, and its expression is much higher at the
onset of mineralization.15–17 In the current experiments,
RANKL protein localized to the hypertrophic chondrocytes
and increased by 30% with daily and intermittent calcitriol
(Figure 7a). OPG expression that also localized to the same
layer of hypertrophic chondrocytes did not change with
calcitriol (Figure 7b). There was good correlation between
RANKL and OPG, R¼ 0.87, Po0.0001. The increase in
RANKL expression in the present study suggests that
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Figure 5 | CaR, IGF-I, and IGBP3 protein expression in chondrocytes increased with calcitriol. (a) Calcium receptor, (b) IGF-I, and (c) IGFBP3
protein expression in the growth plate of all groups in the left panel as denoted by arrows,  65, with the quantification of protein response in
the corresponding right panel. Calcium receptor is localized to the lower proliferating and upper hypertrophic chondrocytes, IGF-I in the
hypertrophic chondrocytes and IGFBP3 in the proliferative zone.
586 Kidney International (2007) 72, 582–591
o r i g i n a l a r t i c l e CP Sanchez and YZ He: Calcitriol and bone elongation
calcitriol enhances mineralization, which has been described
in other studies.18
DISCUSSION
The current findings demonstrate that treatment with either
daily or intermittent calcitriol has similar effects on body and
tibial length, serum calcium, circulating PTH, and on
chondrocyte proliferation and hypertrophy in phosphorus-
loaded animals with renal failure. Our results are in contrast
to the findings of Mehls et al. that daily and not intermittent
calcitriol improved growth in animals with renal failure;4
these differences may be due to the higher PTH and
phosphorus levels, younger age of the animals, and longer
duration of renal failure in the current study. Although the
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Figure 6 | Calcitriol enhanced VDR, FGF23, and FGFR3, all markers of chondrocyte differentiation. Markers of chondrocyte differentiation
(a) VDR, (b) FGF23, and (c) FGFR3 in the hypertrophic chondrocytes in all groups marked by arrows (right panel,  65) and the corresponding
Labeling index (right panel). VDR and FGF23 are localized to the hypertrophic chondrocytes and FGFR3 staining is located both in the
proliferating and upper hypertrophic chondrocytes.
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Figure 7 | RANKL and OPG expression increased in the growth plate during calcitriol therapy in renal failure. (a) RANKL and (b) OPG
protein expression in the growth plate of all experimental groups (denoted by arrows,  65). The corresponding quantification of protein
response is shown in the right panel. Both RANKL and OPG are confined to the upper hypertrophic chondrocytes.
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parathyroid gland was not evaluated in the present experi-
ment, the higher PTH and phosphorus levels may suggest the
presence of nodular hyperplasia, which may have contributed
to calcitriol resistance, poor growth, and absence of PTH
reduction.
The growth plate is a highly organized tissue with various
layers of chondrocytes at different stages of differentiation.
Chondrocyte proliferation is primarily regulated by the
PTHrP-Indian hedgehog-TGF-b feedback loop. We have
previously shown that phosphorus-loaded rats with renal
failure had smaller growth plate with significant reduction in
chondrocyte proliferation most likely owing to a decrease in
PTH/PTHrP receptor expression.19 PTH/PTHrP delays chon-
drocyte differentiation and maintain proliferation by down-
regulating the transcription factor Runx2, activating protein
kinase A and decreasing p57Kip2.20,21 With considerable
decrease in PTH/PTHrP receptor, our results showed an
upregulation of p57Kip2 in phosphorus-loaded rats indepen-
dent of calcitriol. It is unclear whether the decline in PTH/
PTHrP receptor occurred first in the course of renal failure
with subsequent increase in the cyclin kinase inhibitor p57Kip2
that may account for poor growth in advanced secondary
hyperparathyroidism. Further studies are needed to assess the
sequence of events that eventually leads to reduction of
chondrocyte proliferation. The members of the cyclin-
dependent kinase inhibitors Cip/Kip family, including
p57Kip2 and p21Waf1/Cip1, inhibit phosphorylation by binding
to the proliferating nuclear cell antigen preventing DNA
replication.22,23 Our findings suggest that phosphorus load-
ing per se in renal failure can lead to alterations in the
downstream signaling pathways of PTH/PTHrP and upregu-
lation of p57Kip2, which may contribute to inhibition of
chondrocyte proliferation leading to suboptimal growth.
Calcitriol treatment in the current study enhanced PTH/
PTHrP receptor with subsequent increase in cyclin D1, mTOR,
and histone-4. PTHrP using the transcription factor CREB
stimulates cyclin D1 promoter activity via the CRE promoter
element.24 Although calcitriol increased PTH/PTHrP receptor,
the expression of the cell cycle inhibitor p57Kip2 remained
elevated with concomitant upregulation of p21Waf1/Cip1; the
upregulation of both cell cycle inhibitors may promote
chondrocyte differentiation and hinder cell proliferation, and
may explain the lack of growth in the phosphorus-loaded rats
as demonstrated in the current study.
Calcitriol is well known to have dose-dependent effect on
cell proliferation, including chondrocytes. Inhibition of
chondrocyte proliferation occurred with calcitriol greater
than 1010 M and stimulation at concentration lower than
1012 M.25 In higher doses, calcitriol inhibited the progression
of cell cycle from G1 to S phase by decreasing the targets of
E2F transcription factors leading to accumulation of cells in
the G1 phase;
26 this downregulation of DNA replication genes
only occurred in cells with functional VDR.26 The inhibitory
effects of calcitriol on cell proliferation may also be due to the
increase in IGBP-3 and increase in the cyclin kinase inhibitor
p21Waf1/Cip1 through its actions on the vitamin D response
element in the p21Waf1/Cip1 promoter leading to the activation
of the TGF-b signaling pathway.27–29 In this study, there was a
greater increase in p21Waf1/Cip1, IGF-I, IGFBP3, BMP-7, and
FGFR3 during treatment with calcitriol, all markers that
promote chondrocyte maturation.
The maintenance of the columnar architecture is vital
in cell-to-cell contact and cell-to-matrix communication in
the growth plate. Distortions of the growth plate matrix
as shown in our phosphorus-loaded rats may lower
chondrocyte proliferation, alter cell enlargement and delay
cartilage mineralization. Our current results show that
the expression of the matrix protein aggrecan, collagen-
binding protein b1 integrin, and extracellular Col2a1 expres-
sion were much lower in the growth plate of the phosphorus-
loaded rats and calcitriol treatment restored the architecture
of the growth plate and increased the expression of the
matrix proteins. b1 integrins, which are highly expressed in
chondrocytes, are cell surface receptors important in cell
adhesion, migration, and matrix assembly.30 Deletion of
b1 integrin gene was associated with chondrodysplasia,
abnormal shape of the chondrocytes, failure to form columns
in the growth plate, decreased collagen fibril density in the
cartilage matrix, and loss of adhesion to the Col2a1 matrix.8
Although our previous studies have not shown differences
in intracellular Col2a1 and Col10a1, our results showed the
downregulation of b1 integrin and aggrecan in the growth
plate of phosphorus-loaded animals. The problems
with communication between chondrocytes and the pericel-
lular matrix may contribute to the overall decline of
chondrocyte activity in renal failure. Our previous experi-
ments did not show alterations in the growth plate
architecture of rats with renal failure and mild secondary
hyperparathyroidism;19 however, the columnar organization
in the phosphorus-loaded uremic rats is markedly abnormal,
which was restored by calcitriol.
The CaR is crucial in the regulation of PTH secretion and
studies suggest that CaR may play a role in chondocyte
maturation.10 Our experiments show that CaR substantially
declined in the growth plate of phosphorus-loaded animals
with renal failure and restored by calcitriol. The increase in
serum calcium during calcitriol therapy may contribute at
least in part to the upregulation of the CaR, as calcium is
critical to cell growth and enhances chondrocyte differentia-
tion. Rodriguez et al.31 have reported that increasing the
extracellular calcium even in CaR (/) chondrocytes
enhanced chondrocyte differentiation associated with pro-
teoglycan accumulation, mineral deposition, and matrix gene
expression. We have previously reported that calcium loading
in renal failure lead to hypercalcemia with inhibition of cell
proliferation and reduction in circulating PTH.32 Although
serum calcium increased with calcitriol in the current study,
the increment was much lower than our calcium-loaded rats
and hence may not be effective in the inhibition of PTH
secretion in phosphorus-loaded animals.
FGF23, a novel circulating factor essential in phosphorus
homeostasis, is elevated in hypophosphatemic rickets and in
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chronic renal failure.33 Our current results show that FGF23
protein is localized to the hypertrophic chondrocytes and
may participate in chondrocyte maturation. In this study,
phosphorus loading lowered FGF23 in the chondrocytes and
calcitriol enhanced the expression of both FGF23 and one of
its receptor, FGFR3, a well-known inhibitor of bone growth
and chondrocyte proliferation. Calcitriol may affect FGF23
expression through its actions on the vitamin D response
element in the FGF23 promoter or via a VDR-independent
pathway.34,35 We did not measure circulating FGF23, so it is
unclear whether serum levels correlate with FGF23 expression
in the growth plate. As FGF23 is important in phosphorus
regulation, it may play an essential role in cartilage
mineralization. The upregulation of FGFR3 by calcitriol
may contribute in part to the inhibition of bone growth as
demonstrated in the current study.
Osteo/chondroclastic resorption is an important step in
endochondral bone growth. Our previous studies demon-
strated upregulation of gelatinase B/MMP-9 expression and
increase TRAP staining in the chondro-osseous junction of
phosphorus-loaded animals with renal failure. In this study,
we evaluated the expression of RANKL and OPG, which are
essential in osteo/chondroclast activation and function.
RANK and its ligand RANKL are members of the tumor
necrosis factor receptor family that participate in osteo/
chondroclastogenesis by binding to osteoclast/chondroclast
precursors. OPG is a decoy receptor for RANKL and
interferes with the activation of RANK. Both OPG and
RANKL were localized to the same layer of hypertrophic
chondrocytes, which may suggest coupled actions in osteo/
chondroclastogenesis. In agreement with other studies, our
current paper shows that calcitriol increased RANKL without
any changes in OPG expression.36 Several investigators have
demonstrated that RANKL/OPG ratio may be an indicator of
osteoclast activation with an increase at the onset of
mineralization.36,37 The present findings suggest that calci-
triol may enhance osteo/chondroclastogenesis in rats with
severe secondary hyperparathyroidism by targeting the
vitamin D response element in the RANKL promoter
region.38,39
Calcitriol is a standard form of treatment for secondary
hyperparathyroidism in children with chronic renal failure.
Our findings suggest that there is an overall delay in
chondrocyte proliferation and chondrocyte differentiation
in the growth plate of animals with renal failure and
advanced secondary hyperparathyroidism. Calcitriol, whether
given daily or intermittently, is equally effective in the
enhancement of chondrocyte maturation and restoration of
the growth plate architecture. Although calcitriol increased
PTH/PTHrP receptor and associated cell cycle proteins, there
was a greater increase in the expression of the cyclin kinase
inhibitors p57Kip2 and p21Waf1/Cip1 associated with enhance-
ment of the bone growth inhibitor FGFR3; such findings may
contribute to the poor growth demonstrated during calcitriol
therapy in animals with renal failure and advanced secondary
hyperparathyroidism.
MATERIALS AND METHODS
Thirty-six male weanling Sprague–Dawley rats, 6273 g and
2370.6 cm (Harlan Laboratories, Indianapolis, IN, USA), were
housed in individual cages at constant temperature. After 24 h of
acclimatization, 26 animals underwent the first stage of a two-stage
5/6 nephrectomy (Nx) under ketamine and xylazine anesthesia as
described previously.9 After 1 week, the Nx animals underwent total
nephrectomy of the right kidney. Ten rats underwent sham
nephrectomy (Control) in two stages corresponding to the 5/6
nephrectomy. To induce advanced secondary hyperparathyroidism,
all nephrectomized animals were fed high phosphorus diet (Nx-
Phos, 1.2% phosphorus) for the entire duration of the 5 weeks study
period. All Control animals were fed the standard rodent diet. To
ensure equivalent caloric intake, the Control animals were pair-fed
with Nx-Phos animals by providing the amount of food each day to
Control rats that had been consumed the previous day by Nx-Phos
group. All procedures were reviewed and approved by the Research
Animal Resource Center at the University of Wisconsin-Madison
and conducted in accordance with the accepted standard of humane
animal care.
All animals were weighed daily and body length was measured
weekly under anesthesia. Calcitriol was started 24 h after the second-
stage surgery, nine animals received daily calcitriol at a dose of
50 ng/kg/day (Nx-Daily D) and nine rats were given calcitriol three
times weekly at 350 ng/kg/week (Nx-Int D). The last dose of
intermittent calcitriol was given 48 h before killing. Both Nx-Phos
(N¼ 8) and Control (N¼ 10) received saline injections. All
injections were given by intraperitoneal route, using equivalent
volume and at the same time of the day for a total of 4 weeks. The
dose of calcitriol was adapted from our earlier study that showed
changes in the growth plate after 10 days of treatment.9
After 4 weeks of calcitriol, the animals underwent trans-cardiac
perfusion using 4% paraformaldehyde in phosphate-buffered saline
(PBS). At the time of killing, blood samples were obtained and
stored at 801C until biochemical assays for serum calcium,
creatinine, phosphorus, urea nitrogen, and PTH. Blood was
collected 48 h after the last dose of intermittent calcitriol and 24 h
after the last dose of daily calcitriol. The proximal tibiae were
collected, decalcified in 15% ethylenediaminetetraacetic acid in PBS
for 2 weeks and embedded in paraffin.32 Tibial length was measured
between the proximal and distal articular surfaces using a caliper.
Five micrometer sections of the proximal tibia were collected for
morphometric analysis and immunohistochemistry studies as
previously described.32
Serum biochemical determinations
Serum urea nitrogen, creatinine, calcium, and phosphorus levels
were measured using standard laboratory methods. PTH levels were
measured using the Rat BioActive PTH ELISA assay kit, which
detects the full length biologically active form (Immutopics Inc., San
Clemente, CA, USA).
Growth plate morphometry
For morphometric analysis, three 5-mm sections of bone were
obtained, stained with hematoxylin and eosin and viewed under
light microscopy at  25. The total width of the growth plate at the
proximal end of each tibia was measured at equally spaced intervals
using an image analysis software as described previously (Kontron
Instruments Ltd Elektronik 200, Hallbergmoos, Germany).9 The
widths of the zones occupied by hypertrophic chondrocytes and
proliferative chondrocytes were measured by similar method.
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Immunohistochemistry experiments
Immunohistochemistry experiments were performed using methods
described previously.40 All primary antibodies were obtained from
(Santa Cruz Biotechnology, Santa Cruz, CA, USA) unless indicated.
The following primary antibodies were selected to evaluate
chondrocyte proliferation: (a) cyclin D1 at 2 mg/ml, (b) histone-4 at
5 mg/ml, (c) b1integrin at 5 mg/ml, (d) mTOR (mammalian target of
rapamycin) at 8 mg/ml, and (e) PTH/PTHrP receptor at 4.4mg/ml
(Upstate Biotechnology, Upstate USA Inc., Charlottesville, VA,
USA). Chondrocyte maturation was assessed using: (a) CaSR at
5 mg/ml (b), IGF-I at 10 mg/ml (Upstate Biotechnology), (c) IGFBP3
at 10 mg/ml, (d) p57Kip2 at 4 mg/ml, (e) p21Waf1/Cip1 at 8 mg/ml, (f)
FGF23 at 4 mg/ml, (g) FGFR3 at 5 mg/ml, (h) VDR at 5 mg/ml, and (i)
BMP-7 at 5 mg/ml. Osteo/chondroclastic activity was evaluated using
RANKL at 6 mg/ml and OPG at 5 mg/ml. Aggrecan was assessed in the
hypertrophic chondrocytes and Col2a1 protein in the extracellular
matrix after incubation with trypsin.
Slides were viewed at  65 by bright field microscopy, images
were captured using a charge coupled device (CCD) camera control
unit and displayed on a computer monitor. Approximately, 50–60 cell
profiles were assessed in each growth plate. For quantification of the
protein expression, the number of cells expressing the protein was
counted and expressed as percentage of the labeled cells over the total
number of cells where the expression is localized (Labeling Index).40
Statistical analysis
All results are expressed as mean values71 s.d. Data were
evaluated by one-way analysis of variance and comparisons
among groups were carried out using Bonferroni/DUNN post
hoc tests using the StatViews statistical software (SAS Institute,
Cary, NC, USA). The Pearson product moment correlation
coefficient was used to evaluate the relationship between two
numerical variables. For all statistical tests, probability values
less than 5% were considered to be significant.
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